USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
Teens Are Falling Victim to AI Fake Nudes
The Resurrection of Abercrombie & Fitch
Gold Bars, Cash and a Mercedes: A U.S. Senator's Corruption Trial
Boeing Agrees to Felony Plea. Now Its Future Is Up in the Air.
Coinbase’s CEO on the Future of Crypto
McDonald’s Wants To Offer Quality And Value. Can It Do Both?
Will Biden Stay in the Race?
A Troubled Plan to Ship Migrants to Rwanda
Trump Has Broad Immunity
Farm-to-Table Pioneer on Why We Still Need Better Food
All Eyes on Biden, Trump – and CNN
How Ukraine Built a Weapon to Control the Black Sea
The Unusual Economics of the Bilt Credit Card
Southwest Changed Flying. Can It Change Itself?
Zyn pouches, ‘Zynfluencers’ and ‘the Zyndemic’
Sam Altman's Opaque Investment Empire
How ‘Conflict Gum’ Is Helping Fuel Sudan’s Civil War
The Brutal Calculation of Hamas’s Leader
Tesla’s Multibillion-Dollar Pay Package for Elon Musk
The Hidden Life of Google’s Secret Weapon
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained